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Portal vein embolization (PVE) is used to increase the volume and function of the liver that will remain after extensive liver resection. Operative
outcomes are improved in properly selected patients who undergo PVE and experience adequate future liver remnant (FLR) hypertrophy.
Absolute volume and volume change of the FLR after PVE (interpreted in context of liver disease) predict adequate liver function postresection.
Oncologic outcomes following resection in patients with appropriately applied PVE are excellent.
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INTRODUCTION
Major hepatectomy is increasingly used to expand the pool of
patients who are candidates for complete resection of colorectal liver
metastases (CLM) with curative intent. In fact, the current definition of
‘‘resectable’’ liver metastases is that all disease can be removed with
negative margins leaving adequate liver remnant [1]. This new
definition of resectability, not restricted based on number, size or
bilaterality of lesions in the liver, rests on the finding that oncologic
outcomes are good when all disease is resected, but clinical outcomes
relate to the remnant liver, not the resected liver. This realization grew
out of the finding that major technical complications and fatal liver
failure are rare; however, as the limits of resection are tested and
extended hepatectomy is used to remove larger and larger proportions
of liver parenchyma, complications resulting from cholestasis and
impaired synthetic function contribute to morbidity and prolonged
recovery in some patients [2,3].
Recovery from major hepatic resection relates primarily to the
quality and volume of liver that remains after resection (the future liver
remnant [FLR]). Patients with an adequate FLR recover from major
resection rapidly, even in the event of a complication. In contrast,
patients with a truly inadequate FLR may develop no surgical comp-
lications whatsoever but progressively become jaundiced (even with
relatively normal prothrombin time) and eventually die of liver failure
(typically within 90 days after surgery). Patients with a marginal FLR
are vulnerable to a cascade of problems if a surgical complication
occurs—if such patients develop pneumonia or a perihepatic collec-
tion, they may suffer a prolonged, complicated postoperative course
and recovery, or succumb to multiple organ failure. These problems
can occur both in patients with normal livers and in those with diseased
livers when the FLR volume is marginal or inadequate [2,4,5] though
prolonged recovery is more common and death less common in
patients with normal liver than in those with liver disease, in whom
liver dysfunction leads more often to liver failure and death. This
difference likely relates to the difference in regeneration capacity
between normal and diseased livers for regeneration and recovery of
marginal liver function.
Thus, it is not only the size of the remnant liver but also the quality
of the underlying liver affects outcomes after resection—that is, in a
patient with a normal liver, a smaller FLR supports normal functional
recovery, whereas in a patient with a diseased liver (e.g., a cirrhotic
liver or liver damaged by very extensive chemotherapy), a larger FLR
is necessary to ensure adequate liver function. Certainly volume and
liver disease are not the only determinates of outcome, but careful
assessment of liver volume can be used with remarkable efficacy to
reduce the risk of major complications, liver failure and death after
major hepatectomy in general, and specifically in patients who undergo
major resection for CLM.
PVE Background
Portal vein embolization (PVE) has been proposed [6] and is
increasingly used [2,7] prior to major hepatic resection in patients with
normal and diseased underlying liver parenchyma to induce hyper-
trophy and to enhance the function of the FLR, when the preoperative
judgment is made that resection would leave an FLR inadequate to
support posthepatectomy liver function.
PVE is a procedure designed to redirect portal flow to the FLR, in an
effort to increase the volume and function of the FLR prior to extended
resection in patients with a preoperatively assessed inadequate liver
volume.
PVE works because extrahepatic factors that induce liver
hypertrophy are carried primarily by the portal vein, not the hepatic
artery [8,9]. ‘‘Hypertrophy’’ in response to PVE occurs based clonal
expansion of hepatocytes, not simply to increase in volume of the
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existing cells. Liver growth in response to portal flow diversion occurs
in proportion to the stimulus—resection or portal flow diversion of
<10% of liver volume has little effect on regeneration of the remaining
liver; however, progressively increased flow diversion generates a
progressively greater stimulus for nonembolized liver to regenerate
[10,11].
Technique of PVE is important. To ensure adequate hypertrophy,
embolization of portal branches must be as complete as possible so that
recanalization of the occluded portal system is minimized. The entire
portal tree to be resected must be occluded to avoid the development of
intrahepatic portoportal collaterals that may limit regeneration [12] and
to avoid diversion of portal flow to tumor-bearing liver which can
lead to tumor progression [13]. When all tumor-bearing liver is
systematically embolized, no tumor progression occurs during the wait
period for hypertrophy after PVE [14].
PVE can be performed by any of three standard approaches: the
transhepatic contralateral (i.e., portal access via the FLR), transhepatic
ipsilateral (i.e., portal access via the liver to be resected), and
intraoperative transileocolic venous approaches. These approaches are
chosen on the basis of operator preference, type of hepatic resection
planned, extent of embolization (e.g., right PVE with or without
extension to segment IV), and type of embolic agent used.
We prefer the approach which most carefully preserves the FLR, as
that is the objective of PVE. Specifically, we use an ipsilateral
approach, that is, the liver to be resected is punctured and PVE
performed without puncture of the PV in the FLR, as is required by the
less technically challenging contralateral approach. When extended
right hepatectomy is planned, the segment IV branches are embolized
first using reverse curve catheters. Small particles are infused (usually
microspheres) which assure outflow obstruction. Coils are placed more
proximally in the portal branches after outflow occlusion. Coils prevent
inflow recanalization, but are placed carefully to avoid interference
with planned liver transection. After segment IV branch embolization
is complete, the right PV branches are occluded in a similar fashion.
Completion portogram should demonstrate portal flow only to the
FLR.
PV occlusion can be accomplished by portal ligation at open
operation. However, portal ligation does not allow segment IV flow
diversion, and in the case of extended right hepatectomy, assures portal
flow to tumor bearing liver, which may lead to unwanted progression of
disease prior to surgery. Further, portal ligation is associated with
almost 100% recanalization of flow into the right liver due both to
portoportal collaterals and possibly to arterioportal filling [12,15].
Thus portal ligation is a much less efficient method of flow diversion to
induce hypertrophy than PVE [10,16,17] and provides significantly
inferior results to PVE in terms of FLR hypertrophy [16,18,19].
Optimal flow diversion is critical to optimize outcome because the
degree of stimulus (portal flow) is directly related to the degree of liver
growth after PV ligation or embolization. Achievement of maximal
stimulus is necessary to ensure adequate growth of the small FLR in
preparation for extended hepatectomy.
Even patients with bilateral CLM can benefit from two-
stage approaches to clear the FLR of metastatic disease in the
first operation, followed by PVE to increase the volume and function
of the tiny FLR, enabling second-stage (second operation) major
resection of contralateral disease enabling remarkable long-term
outcomes [20].
Substantial evidence has mounted that PVE should be considered in
many patients who are considered for major hepatectomy. Integral
to the discussion of PVE is the discussion of liver volume, as liver
volume and function are linked, and liver volume measurement guides
utilization (and not overuse) of PVE; volumetric response to PVE also
predicts outcome. This review reiterates evidence supporting the use of
PVE in preparation for major liver resection particularly in treatment
for CLM, reviews the safe limits of resection, and discusses the
excellent outcomes of resection following PVE and major hepatectomy
for CLM.
THE LIVER VOLUME–LIVER FUNCTION LINK
Liver volume and liver function are linked [21]. In fact, there is a
linear mathematical correlation between total liver volume and patient
size (expressed as body weight or body surface area [BSA]) [22]—
larger patients have larger livers; smaller patients, smaller livers.
Realization that outcome from major liver surgery relates importantly
to the volume and function of the liver that remains after resection
(FLR) has led to objective measurement of the FLR prior to resection,
and to analyses of outcome from resection based on FLR volume.
FLR Volume—Standardized Volumetry
Early in the evolution of understanding about the liver volume—
liver function link, the safe extent of surgery was variously described as
resection leaving a remnant of anywhere from 60% to 35% of the liver
[23–27]. Differences in reported safe limits of resection related to
differences in methods of assessing the FLR, and more recently to the
lack of inclusion of patients with very small FLR volumes in studies
designed to assess volume limits of safe resection (which made it
impossible for authors to determine the evolution of liver function after
resection in small volume patients). The method of measuring FLR
volume determination can influence the results of studies on the liver
volume [28]. Specifically two methods of liver volumetry are used.
A standardized method of liver volume calculation is preferred.
This method utilizes computed tomographic (CT) measurement of the
FLR (the FLR is not diseased, and thus is accurately measured by CT)
[29] but calculates the TLVon the basis of BSA, which does not vary
based on liver disease or tumor involvement of the liver to be resected
[28]. The FLR volume is expressed as a percentage of the TLV such
that standardized TLV¼ (FLR volume from CT) (TLV from
formula). FLR volume calculated in this manner—on the basis of the
standardized TLV—is referred to as ‘‘standardized FLR volume.’’
Future measurements of the FLR volume can be standardized to the
same TLV denominator to allow accurate comparison of FLR volume
before and after interventions. This is the best-validated method of
FLR volumetry [21].
An alternative method of FLR volumetry has also been reported
[30] which uses CT both for FLR volume measurement and for TLV
measurement. This alternate method then requires measurement of the
tumor volumes in the liver to be resected and development of a
‘‘corrected TLV’’ by subtracting the measured tumor volumes from the
measured TLV. This alternative method introduces error into both pre-
and post-PVE volume determinations because (1) the liver is diseased
(either contains tumors, or in the case of liver disease may be enlarged
or shrunken), (2) TLV may be altered by prior treatment including
chemotherapy, (3) additive measurement error occurs because of the
standard error in liver volume determination combined with the
standard error in tumor volume determinations (usually multiple
irregular tumors in patients with CLM), and (4) different TLV
denominators are used to calculate FLR volume before and after PVE
because the actual TLV changes after PVE. The lack of standardization
of TLV to patient size using body weight or BSA reduces the value of
the FLR volume calculation and fails to recognize the significance of
the liver volume–patient size correlation [31].
Significance of the Absolute FLR Volume
The safe limit of resection in an individual patient depends on the
degree of underlying liver disease. There are three benchmarks for safe
resection:>20% of the standardized TLV in patients with normal liver,
>30% of the TLVand in patients with diseased liver,>40% of the TLV
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in patients with (well compensated) cirrhosis (Fig. 1). This limit is
often expressed as a continuum. Placement of an individual on that
continuum can be straightforward (in the case of a thin patient who has
never been treated with chemotherapy) or difficult (a patient with fatty
liver disease and treatment with chemotherapy for a year or more).
Determination of the safe limits of resection in such ‘‘gray zone
patients’’ is discussed later in this paper. Understanding of the data
which define the limits of safe resection described herein and the safety
buffer that they provide is worthy of discussion, particularly because of
the concern that surgeons express regarding the risk associated with
resecting down to the proposed limit of 20%.
Normal Liver—Volume Limits for Safe Resection
For patients with normal liver, several different limits have been
proposed for the minimum safe FLR volume, ranging from a high of
30% of TLV [32–34] to a low of 20% of TLV [1,2,31,35]. An early
study from our institution found a minimum safe FLR volume of 25%
of the standardized TLV in patients who underwent extended right
hepatectomy [28], but this initial study used standardized TLV
calculated using the Urata formula (derived from young, thin patients)
[36], which we subsequently found significantly underestimated the
TLV for Western patients. We developed a more accurate formula
following analysis of a large population of patients from the Americas
and Western Europe [37] which has been shown in meta-analysis to be
the most accurate, least biased formula for estimation of TLV [21].
Using the new formula in a study of the relationship between outcome
after extended right hepatectomy and standardized FLR volume in
patients with FLR volumes as small as 11% of TLV [38], we showed
that 50% of patients with an FLR volume 20% of TLV suffered
complications, versus only 13% of patients with an FLR volume>20%
of TLV (Fig. 2). This study suggested a new, smaller cutoff, and was
likely more accurate because of the use of a more accurate TLV to
which the FLR was standardized (i.e., TLV calculated from an
appropriate formula) and because this study, unlike other studies that
suggest the limit is 25% [39,40], included patients with very FLR
volumes well below the actual safe limit of 20%. It is worthy of note
that in this study, none of the patients died, even those with FLR
volume of only 11%.
Two large follow-up studies confirmed the 20% FLR limit for
patients with normal liver [31,41]. The first [41] used established
definitions for hepatic dysfunction [42,43] and hepatic insufficiency
[43] and used receiver operating characteristic analysis to assess the
volume limit for safe resection in a series of 112 patients who
underwent major or extended hepatectomy at one institution between
1995 and 2006. Using systematic standardized liver volumetry, overall,
major and liver-related complications, hepatic dysfunction or insuffi-
ciency, hospital stay and 90-day mortality rate were shown to be
significantly more common in patients with a standardized FLR of
20% of TLV compared to those with larger FLR volumes. The largest
study from Kishi et al. [31] included analysis of 301 patients who
underwent extended right hepatectomy, again using standardized
volumetry and an objective, established definition of liver insufficiency
[4]. Importantly, this study examined outcomes in patients with
standardized FLR volume 20% of TLV, 20.1–30% of TLV, or >30%
of TLVand showed that liver insufficiency and death from liver failure
were no more common in patients with FLR volume 20.1–30% of TLV
than in patients with FLR volume>30% of TLV (Fig. 3). However, the
group with FLR volume 20% of TLV experienced an increased risk
of liver insufficiency and death from liver failure (P< 0.05). Finally, it
is worthy of note that preoperative chemotherapy was given to 56% of
patients in that study, including 58% of the patients with FLR 20.1–
30% of TLV. However, administration of chemotherapy (median 6
cycles) did not imply liver disease or the need for a larger liver volume
to assure safe resection, undermining the misguided notion that ‘‘just
giving’’ chemotherapy is enough reason to perform PVE in patients
with intermediate liver volumes [32–34] or using PVE as an
‘‘approach’’ in patients with CLM who need chemotherapy and major
resection [44].
Many authors use an arbitrarily determined cutoff for safe resection:
an FLR volume of 30% of TLV [32–34]. There are no studies or
data to support this volume limit—it is simply stated and used by
the referenced authors. The data from Kishi et al. undermine any
hypothesis that PVE is indicated across the board in patients with this
volume limit.
Thus, the minimum safe FLR volume in patients with normal liver
was established as >20% of the standardized TLV. This limit
was published in 2006 in the consensus statement made following a
consensus conference on hepatic colorectal metastases sponsored by
the American Hepato-Pancreato-Biliary Association and cosponsored
by the Society for Surgery of the Alimentary Tract, Society of Surgical
Oncology, GI Symposium Steering Committee, and The University of
Texas M. D. Anderson Cancer Center [1].
Diseased Liver—Volume Limits for Safe Resection
There have been no studies of the minimum safe FLR volume for
patients with liver disease except in patients with well-compensated
cirrhosis. Few patients with cirrhosis present with CLM; however, the
methodology used to determine the safe limit of resection, and
the findings in the study of cirrhotics, patients on the opposite pole of
the continuum of liver disease from patients with normal liver,
confirms the correlation between liver volume and liver function, and
the importance of consideration for degree of underlying liver disease
[1,5,23].
Briefly, two studies examined outcome following hepatic resection
in cirrhotic patients [5,23]. Both used standardized volumetry, and both
found a safe limit of resection of >40% of the TLV. Kubota et al. [23]
demonstrated that cirrhotic patients with normal preoperative liver
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Fig. 1. Minimum FLR volume needed for safe hepatic resection in
patients with normal liver, intermediate liver disease, or cirrhotic liver.
Adapted from Zorzi et al. [57], with permission.
Fig. 2. Complication rate stratified by standardized FLR volume
(%FLR) in patients with normal underlying liver. Fifty percent of
patients with %FLR 20% experienced complications, compared to
only 15% of those with %FLR> 20% (P¼ 0.02). Adapted from
Abdalla et al. [38], with permission.
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function who underwent major hepatectomy developed hyperbilirubi-
nemia when FLR volumes were small but did not develop
hyperbilirubinemia when FLR volumes were large (>40% of TLV).
Shirabe et al. [5] took this line of inquiry one step further, in a
subsequent study of cirrhotic patients who had undergone right
hepatectomy. They demonstrated that patients who died of liver failure
had significantly smaller FLR volumes than patients who did not die of
liver failure (P< 0.008). Further, using standardized liver volumetry
(FLR volume standardized to BSA), they demonstrated that the
incidence of liver failure in patients with an FLR volume of <250ml/
m2 BSAwas 38%, versus 0% in patients with an FLR volume>250ml/
m2 (P< 0.001) [5].
VOLUME SHIFT TO FLR AFTER PVE
Given that liver volume and liver function are linked and that
the minimum safe FLR volume for resection is 20% of TLV in patients
with normal liver and 40% of TLV in patients with cirrhosis, a logical
next question is whether PVE can increase the volume of the FLR, and
whether the increased volume an indicator of increased function. Said
differently, can PVE shift liver function from the embolized liver (the
liver to be resected) to the FLR?
More than 75 studies published in peer-reviewed journals have
demonstrated that the FLR volume increases after PVE performed
prior to major hepatectomy [7]. A recent meta-analysis of 1,088
patients who underwent PVE for a variety of indications across a
spectrum of normal to cirrhotic liver revealed that the FLR volume
increased following PVE in every study [7]. The overall morbidity
rate for PVE was 2.2%, and no deaths due to PVE were reported.
Eighty-five percent of patients underwent resection after PVE, and the
incidence of transient liver failure following resection was only 2.5%;
the mortality rate from liver failure was 0.8% [7].
These data demonstrate that PVE does increase FLR volume and
that resection after PVE is safe. In addition, both the incidence of
liver failure and the incidence of death due to liver failure in this meta-
analysis were dramatically less than the corresponding rates for major
and extended resection in series in which patients did not undergo
preoperative PVE.
Three objective pieces of data demonstrate a shift in liver function
from the embolized liver to the FLR after PVE [45–47]. The first study
examined ICG excretion, liver volume, and bile volume in the FLR
before and after PVE [47]. The amount of ICG excreted by the left lobe
(FLR) as a proportion of total ICG excretion increased 20.1%, and the
volume of the left lobe as a proportion of TLV increased 8.3%,
indicating an actual shift in liver function to the nonembolized liver
after PVE. In fact, the shift in function was greater than the shift in
volume.
The second study examined liver volume and function using
computed tomography (CT) and technetium-99m-galactosyl human
serum albumin scintigraphy before and after PVE [45] and confirmed
both a volume and a function shift to the nonembolized lobe after PVE.
Of note, no patients with an FLR volume >40% of TLV experienced
postoperative liver failure, whereas patients with an FLR volume
<34% of TLV did experience liver failure. Patients without liver
failure experienced significant increase in FLR volume after PVE
whereas patients with liver failure did not have a good FLR volume
response to PVE.
Finally, a case report demonstrated an actual shift in bile flow to the
FLR after PVE [46]. In this study, percutaneous transhepatic catheters
in the embolized and nonembolized sectors of the liver allowed
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Fig. 3. Liver insufficiency based on future liver remnant volume (FLR). Incidence of postoperative liver insufficiency (A) and death due to liver
failure (B) according to preoperative standardized FLR volume [sFLR (%)]. These data show that patients with sFLR (%) 20.1–30% have no
more liver insufficiency or death than those with sFLR (%)> 30%. Adapted from Kishi et al. [31], with permission.
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measurement of bile flow and bile concentration before and after
embolization. Before PVE, the FLR (36% of TLV measured by CT
volumetry) provided 72% of bile clearance. Jaundice persisted despite
complete drainage of the liver. Following PVE, the FLR volume
increased 23%, but bile clearance in the FLR increased 84-fold, and
the jaundice cleared. Resection was subsequently completed. Thus,
overall liver function improved after PVE, and there was an objective
shift in liver function to the nonembolized liver following PVE [46].
Making High-Risk Patients Low Risk With PVE
As described above, PVE can allow patients with an initial FLR
volume 20% of TLV to experience a postoperative course similar to
that of patients with a larger initial FLR volume, and that the true cutoff
for safe surgery is 20%, not 30% [31]. In that study of 301 consecutive
patients who underwent right hepatectomy extended to all or part of
segment 4 (extended right hepatectomy), known risk factors for liver
insufficiency were studied, including FLR volume, and the incidences
of liver insufficiency and death from liver failure. Patients were divided
into three groups: those with FLR volume 20% of TLVat the time of
resection, those with FLR volume 20.1–30% of TLV, and those with
FLR volume >30% of TLV (Fig. 3). Liver insufficiency was defined
as a postoperative bilirubin level reaching 7mg/dl, as previously
described [4]. Multivariate analysis revealed that BMI >25 kg/m2,
intraoperative blood transfusion, and FLR 20% of TLV indepen-
dently predicted postoperative liver insufficiency (odds ratio 2.18, CI,
1.34–7.54). Further, patients with a pre-PVE FLR volume 20% of
TLV who underwent PVE and experienced FLR growth to >20% of
TLV had a postoperative course similar to that of patients with FLR
volume >20% of TLV without PVE. These patients post-PVE did not
have a postoperative course similar to patients operated with an FLR
20%, which strongly suggests that the risk profile was effectively
decreased in this high-risk population.
A prospective study demonstrated that PVE has no benefit in
patients with normal liver and an adequate FLR volume [48].
Specifically, patients undergoing right hepatectomy were alternately
allocated to PVE versus no PVE. This study is misunderstood and
misquoted as demonstrating that PVE is not indicated in patients with
normal liver. In fact, the study showed that PVE is not indicated in
patients with normal liver with an FLR volume >30%. As expected,
PVE caused no harm, but did not reduce the incidence of postoperative
complications compared to no PVE in this group of patients without
indication for PVE. Restated, this evidence is valuable and supports the
contention that PVE is not indicated for patients with FLR volume
30% of TLV. This study does not, however, demonstrate that patients
with normal liver do not need PVE, as patients at risk for inadequate
FLR volume after resection were not studied. Analysis of segmental
liver volumes demonstrates that the vast majority of patients without
tumor-related volume shift in the liver have a left liver volume 30%
of TLV, thus need for PVE before standard right hepatectomy should
be uncommon (but not unheard of) [49].
The same study [48] demonstrated that PVE is beneficial before
right hepatectomy in patients with cirrhosis. Postoperative complica-
tions, duration of intensive care unit stay, and duration of hospital
stay were significantly decreased in cirrhotic patients who underwent
right hepatectomy after PVE versus those who underwent right
hepatectomy without PVE. Patients with cirrhosis who underwent PVE
had a mean FLR of 35% of TLV—an indication for PVE in
cirrhotic patients according to the work of Kubota et al. [23] described
above. Thus, it is not surprising that this aspect of the study
demonstrated a benefit of PVE compared to no PVE (cirrhotic patients
without PVE had a mean FLR of 39% of TLV). The proportion
of patients with one or more complications and the incidences
of pulmonary complications, ascites, and liver failure were lower in the
PVE group (all P< 0.05).
Volumetric Response to PVE—The Importance
of Degree of Hypertrophy
The volumetric response to PVE, specifically the degree to which
FLR hypertrophy occurs, is a very important component to under-
standing the regenerative capacity of the individual patient’s liver, and
can give a critically important clue to which patients with ‘‘gray zone’’
intermediate livers with difficult-to-quantify liver disease will do well
with resection and which will not. Data are revealing, as follows.
The first observation that the degree of hypertrophy (DH) or %
increase in FLR volume after PVEmight be important came from Hirai
et al. [45] who proposed that FLR hypertrophy in response to PVE
might be prognostic when a single patient died postresection post-PVE
did not experience hypertrophy in response to PVE. This finding was
reiterated when one patient experienced liver insufficiency and one
died of liver failure after right hepatectomy post-PVE, and both failed
to experience FLR hypertrophy in response to PVE [48]. In both
studies, those who experienced liver growth did well. A follow-up
study showed that no deaths occurred after right hepatectomy and PVE
in cirrhotic patients with>10% DH, and all deaths occurred in patients
with <10% DH. Although less relevant to patients with CLM (because
these studies are in cirrhotic patients), the groundwork was laid to
demonstrate that DH was a critical factor in determining safety of
resection post-PVE.
We subsequently demonstrated that both FLR volume and DH can
be used together to determine which patients have low risk for
complications among patients with normal livers in a study including
primarily patients with CLM [41]. As discussed above, this study
demonstrated the cutoff for safe resection is 20%. Any complication,
major complication, liver-related complication, hepatic dysfunction
and hepatic insufficiency were statistically significantly more common
in patients with FLR volumes 20% vs >20%. Further, in this
population with normal underlying liver, overall and liver complica-
tions, and hepatic dysfunction were more common in patients with
5%DH than those with DH>5%. Finally, global, major, liver-related
complications, hepatic dysfunction and insufficiency, and death within
90 days of surgery were less common in patients with both FLR>20%
and DH >5% compared to those with either FLR 20% or DH 5%
(Table I).
Thus in patients with severe liver disease, DH >10% predicts low
risk for complications, and in patients with normal liver DH >5%
predicts low risk. When patients have some degree of underlying liver
disease, for example, after extended chemotherapy for CLM, whether
determined by liver biopsy or findings at surgery or laparoscopy, the
response to PVE helps to determine whether surgery entails high or
low risk. We generally elect not to resect patients whose DH is 5%
post-PVE.
CHEMOTHERAPY AND HYPERTROPHY
AFTER PVE
Many patients with CLM require both chemotherapy and PVE. The
question is often asked whether chemotherapy impairs hypertrophy
in response to PVE. Bevacizumab is a humanized monoclonal
antibody that targets vascular endothelial growth factor (VEGF), and
was the first angiogenesis inhibitor approved by the U.S. Food and
Drug Administration for treatment of CLM. Without actual clinical
study, concerns were raised that VEGF inhibition might impair
liver regeneration [50]. We chose to objectively study the question, and
found that neither systemic chemotherapy nor chemotherapy with
bevacizumab had a significant impact on liver hypertrophy in response
to PVE (Fig. 4). Others have used chemotherapy and PVE together
with excellent results. We routinely utilize chemotherapy with
bevacizumab with PVE with excellent results [20,51].
Journal of Surgical Oncology
964 Abdalla
ONCOLOGIC OUTCOMES OF LIVER
RESECTION FOR CLM FOLLOWING PVE
Oncologic outcomes following resection with PVE are excellent.
Early study from Europe demonstrated 37% 5-year overall survival
following resection of CLM following PVE. The patients in the
study were considered unresectable without PVE, building on data for
patients treated with hepatic resection following PVE with other
pathologies. A subsequent study examined patients with CLM who did
or did not require preoperative PVE. Those who underwent PVE were
considered unresectable without PVE based on liver volumetry.
Survival was comparable independent of initial resectability or the
use of PVE: 5-year overall survival with PVE 38% versus 5-year
overall survival without PVE 40%. Disease-free survival was also
similar.
Patients with bilateral CLM are increasingly considered for
resection [20,52,53]. Two-stage surgery has been proposed for selected
patients as a planned strategy to remove all the disease and to increase
safety of resection. In the initial description of two-stage surgery for
CLM, the major hepatectomy was performed first, and following
hypertrophy of the disease-containing FLR, second resection was
performed to clear the remnant of disease [52]. This approach was
associated with significant complications, and with progression
of disease in the FLR but results were acceptable. The advent of
PVE allowed reversal of this approach. The first step was rather to
perform minor resections in the FLR, rendering it free of disease.
Subsequent PVE led to increase in the volume of the now disease-
free FLR, and second-stage resection could be performed. Some have
proposed ablation in the remnant before PVE rather than first-
stage surgery [54], but results are disappointing using any approach
with RFA when resection is feasible [55,56].
Rather, two-stage surgery with PVE has revealed impressive results.
The first study, from Jaeck et al. [53] revealed that the 3-year overall
survival rate among patients who completed two-stage surgery
with PVE (mean 8 tumors per patient) reached an impressive 54%.
Seventy-five percent of patients who underwent first-stage surgery
successfully completed therapy. We built on this approach, taking
another imperative step in treatment of patients with advanced
CLM. We treated all patients with preoperative chemotherapy, and in
responders, proceeded with two-stage resection with or without PVE as
indicated objectively by volumetry of the FLR [20]. We also compared
the outcomes in patients who underwent two-stage surgery to those
who underwent one-stage surgery after chemotherapy during the
same time period of study. We found that selection of patients based on
response to chemotherapy, recovery from first-stage surgery, adequate
FLR volumetry (57% of patients who underwent two-stage hepatect-
omy required PVE) and on restaging pre-second-stage surgery, we
could achieve even better long-term outcomes. Specifically, among
two-stage patients with a median 7 CLM per patient, 3-year overall
survival was 86%—similar (in fact nonstatistically superior) to
patients who underwent one-stage surgery (75%) with a median
of only 2 CLM. Similarly, disease-free survival was similar as well
(3-year disease-free survival after two-stage resection 51% vs. 39% in
the one-stage group). We are in the process of updating our data with a
larger series which substantiates continued survival benefit at 5-years
post-chemotherapy plus two-stage resection in a larger cohort of
patients (unpublished data).
CONCLUSIONS
PVE is an integral part of the treatments for CLM, as recognition
that resection leaving an adequate liver remnant expands the pool of
candidates for resection of complex liver metastases [1]. Indications
for PVE currently rely on objective measurement of FLR volume using
standardized volumetry. Consensus and reassessment of data confirm
the indications for PVE fall along a continuum depending on the
degree of underlying liver disease. PVE is indicated in patients with
normal liver and FLR volume 20% of the standardized FLR, in
patients with severe underlying liver disease with FLR volume 30%
and in well-compensated cirrhotic patients with FLR 40%. Further,
the response to PVE is prognostic. When the degree of hypertrophy
following PVE is >5%, risk for complications, liver insufficiency and
failure, and death from liver failure are low, especially when target
FLR volume is reached. A greater degree of hypertrophy (>10%) may
indicate low risk in severe liver disease patients, such as cirrhotic
patients. Analysis of degree of hypertrophy helps to determine the
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TABLE I. Short-Term Clinical Outcome by Standardized Future Liver Remnant Volume, Degree of Hypertrophy and Combined Criteria
Standardized future liver remnant (sFLR) Degree of hypertrophy (DH) sFLR or DH
20% >20% Pa 5% >5% Pa 20% or5%
>20% and
>5% Pa
Any complication 90% 39% 0.003 83% 39% 0.006 80% 37% 0.003
Major complication 50% 16% 0.028 42% 17% NS 47% 14% 0.011
Liver-related complication 90% 23% <0.001 83% 22% <0.001 80% 20% <0.001
Hepatic dysfunction 90% 11% <0.001 83% 9% <0.001 80% 6% <0.001
Hepatic insufficiency 30% 2% 0.009 17% 4% NS 20% 2% 0.034
Death within 90 days 10% 2% NS 8% 2% NS 13% 0% 0.049
aw2 test or Fisher’s exact test. Adapted from Ribero et al. [41], with permission.
Fig. 4. Chemotherapy with or without bevacizumab does not impair
regeneration following PVE. Changes in absolute future liver remnant
volume after portal vein embolization in patients without chemo-
therapy (solid line), and with chemotherapy with bevacizumab (dotted
line), and without bevacizumab (dashed line), P¼ 0.35. Values are
mean standard deviation. Adapted from Zorzi et al. [51], with
permission.
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functional capacity of patients that lie in the gray zone of ‘‘liver
disease’’ until we have better determinates of future liver function.
Certainly volume alone and change in volume are not the only
factors that determine outcome, but these can be used with PVE to
dramatically reduce the risk of major resection in patients with CLM,
even some patients with extensive bilateral CLM, and lead to excellent
oncologic outcomes. Overuse of PVE is a risk—though complication
rates are low from PVE when applied for appropriate indications by
skilled interventional radiologists, PVE, like any patient intervention,
cannot used ‘‘just because’’ there is an impression that it is needed.
Continued study and careful utilization based on volumetry is needed.
Finally, given the current level of evidence, the following statement,
originally made in 2001, appears to remain true today: ‘‘A randomized
trial cannot be recommended to test the efficacy of PVE, for it would be
unethical to deny the benefit of the technique and safer resection to
patients who are otherwise poor candidates for resection based on
inadequate liver size or function’’ [2].
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